Objective: Although several studies have described an association between Alzheimer disease (AD) and genetic variation of mitochondrial DNA (mtDNA), each has implicated different mtDNA variants, so the role of mtDNA in the etiology of AD remains uncertain.
Both genetic and environmental factors contribute to the risk of developing Alzheimer disease (AD), with heritability estimates of up to 79%. 1 Variants in 3 genes (APP, PS1, and PS2) cause rare Mendelian forms of the disease, and 10 loci increase susceptibility for the more common late-onset form. 2 Although known genetic variants account for 32% of the genetic variation in AD, most of the genetic variance associated has yet to be attributed to specific loci.
Progressive mitochondrial dysfunction has been reported in the postmortem AD brains 3 and non-neural tissues, 4 implicating a systemic defect of oxidative phosphorylation. Thirteen essential respiratory chain proteins are synthesized from maternally inherited mitochondrial DNA (mtDNA). Several studies have reported the association of different mtDNA haplogroups or specific mtDNA single nucleotide polymorphisms (SNPs) with AD, with both concordant and conflicting results (table 1). Many of these studies were small and had limited power, but 2 of the larger studies reached different conclusions. In 170 AD case patients and 188 controls, mt.9698T, mt.11467G, mt.12308G, mt.12372A, and mt.16270T were associated with AD. 5 These SNPs are found almost exclusively with haplogroup UK. However, in 936 AD case patients and 776 controls, mt.4336C and mt.15883T were associated with AD 6 and fall within haplogroup H. mt.4336C defines subhaplogroup H5a, which can then be further subtyped into subhaplogroup H5a1, based on mt.15833T. 6 In an attempt to resolve this issue, we tested mtDNA variation for association with AD in a large cohort of AD case patients and age-matched controls from 3 Caucasian populations.
METHODS
We studied 138 mitochondrial variants present on the Illumina 610-Quad chip genotyped in 4,133 AD case patients and 1,602 elderly, ethnically matched controls from the United Kingdom, United States, and Germany as part of the Genetic and Environmental Risk for Alzheimer's Disease Consortium 1 (GERAD1) study.
The GERAD1 sample has been extensively described elsewhere. 1 All DNA samples were genotyped at the Sanger Institute (Cambridge, UK) on the Illumina 610-Quad chip. Included in the array were the variants used to define haplogroup H5 and its subgroups, H5a and H5a1 (mt.456CϾT, mt.4336TϾC, and mt.15833CϾT, respectively) and 4 variants found on haplogroup UK (mt.11467AϾG, mt.12308AϾG, mt.12372GϾA, and mt.9698CϾT), which were previously associated with AD. 5,6 Stringent quality control filters were applied to remove poorly performing samples using tools implemented in PLINK v1.05 (http://pngu.mgh. harvard.edu/ϳpurcell/plink). 1, 9 We excluded individuals with missing genotype rates Ͼ0.01, those with inconsistencies between reported gender and genotype-determined gender or ambiguous genotype-determined gender, or those who appeared to be of non-European ancestry. We also examined genetic relatedness and only retained one of each pair of individuals with an identity-by-descent estimate Ն0.125 (the level expected for first cousins). After quality control, 3,250 case patients and 1,221 elderly controls remained. We studied all 138 mitochondrial SNPs, including low-frequency variants (minor allele frequency Ͼ0.01%). Variant frequencies were compared in case patients and controls: 1) on an individual SNP-by-SNP basis using Pearson's test ( p) and 2) across the entire data set by permuting the disease status ( p*), an approach that partially accounts for the phylogenetic structure of the data. All statistical analysis was carried out in PLINK (v2.050) using a single allele-based model. Published data reporting the same mtDNA SNPs were compiled into a single pooled analysis using the same statistical approach. Power calculations were performed using Genetic Power Calculator. 10
Standard protocol approvals, registrations, and patient consents.
This study received national ethical approval. Written informed consent for the research was obtained for all patients who were participating in the study.
RESULTS
We observed some evidence for association between individual mtDNA SNPs previously implicated and AD within subsets of samples, dependent on geographical location. However, no single SNP was consistently associated with AD across all 3 cohorts, and the p values did not withstand a Bonferroni correction to account for multiple statistical testing. Permutation analysis of the entire dataset also showed no significant association between any one SNP and AD, either within each cohort in isolation or when all 3,250 AD case patients and 1,221 controls were pooled. There was no evidence of gender-specific association with any SNP nor any evidence of an interaction with APOE. Power calculations showed that we had Ͼ80% power to detect the previously reported associations 5,6 (assuming 2-tailed significance and ␣ ϭ 5%) with mt.4336C (power ϭ 83.0%), mt.9698T (100%), mt.11467G (100.0%), mt.12308G (100.0%), mt.12372A (100.0%), mt.15833T (94.7%), and mt.16270T (100.0%), even though the control group was smaller than the disease group. A meta-analysis of the current data and previously published studies showed no evidence of association between these 7 variants and AD ( figure) . DISCUSSION We report the largest study of mtDNA variation in AD to date. In addition to the major European haplogroups, our data include variants that define subhaplogroup H5 and its further subdivisions H5a and H5a1 (mt.4336TϾC and mt.15833CϾT, respectively), along with 4 vari-ants found on haplogroup UK (m.11467AϾG, m.12308AϾG, m.12372GϾA, and m.9698CϾT). Our findings fail to replicate previous studies reporting associations with either single genetic variants or specific mtDNA haplogroups. How can we explain the previous findings? The strict maternal inheritance of mammalian mtDNA and the associated lack of intermolecular recombination renders mtDNA genetic association studies particularly vulnerable to a population stratification effect. 11 This increases the chance of detecting a falsepositive disease association. 12 In addition, given that the size of any genetic effect is likely to be small, a reliable association study requires a very large sample size to deliver a consistent result. 13 Although our findings show that the evidence linking inherited mtDNA variants to AD is not compelling, the relative contribution of specific mtDNA variants could vary in different ethnic groups, possibly through an interaction with environmental factors and different nuclear genes. 14 In practice, this means that the specific mtDNA variants that fail to show an association with disease in this study could be associated with disease in a different ethnic population. Geographic variation in allelic association could also arise through homoplasy. Homoplasy is the recurrence of mutations on different branches of the mtDNA phylogeny in different parts of the world. Homoplasy accounts for up to 20% of mtDNA variation and often involves nonsynonymous substitutions. 15 This raises the possibility that haplogroup markers tag different homoplastic functional variants in different populations. If the homoplasies are having a functional effect, this would lead to different haplogroup associations in different studies across the globe. Finally, it is possible that geographic differences in the fine detail of the subhaplogroup structure of mtDNA could account for inconsistencies between studies. This situation has been described for the primary mitochondrial disorder, Leber hereditary optic neuropathy (LHON). LHON is a maternally inherited form of blindness primarily due to 1 of 3 mutations of mtDNA: mt.11778GϾA, mt.14484TϾC, or mt.3460GϾA. The clinical penetrance of LHON is influenced by common polymorphic variants of mtDNA. 16 Specific subbranches of haplogroup J are associated with either an increased or decreased risk of visual failure in different populations, largely due to specific differences in the cytochrome B protein sequence. 17 A similar situation could exist for AD, but resolution of the issue will only be possible through high-resolution genotyping in very large cohorts of patients and carefully matched controls, ideally at the whole mtDNA genome level. Results for the fixed a and random b effects models are shown. The size of the central box on the figure corresponds to the relative study size in each case. The diamond shows the results of the meta-analysis. Current ϭ data from the study reported here; L95 ϭ lower 95% confidence interval; OR ϭ odds ratio; U95 ϭ upper 95% confidence interval; Z ϭ z score.
